American Laboratory Products Company Merges with GeneProof

American Laboratory Products Company, Ltd. (“ALPCO”), a specialty in vitro diagnostics company, today announced a merger with GeneProof a.s. (“GeneProof”), a leading molecular diagnostics company based in Brno, Czech Republic. The combination creates a global market leader... - April 21, 2022

ALPCO Announced Its Support of the Ukrainian People in a Company-Wide Communication to Its Employees

ALPCO (Salem, NH) announced its support of the Ukrainian people in a company-wide communication to its employees. The message outlined the company's contribution to aid refugees through the American Red Cross and Project Hope in the amount of $5,000 each. Additionally, ALPCO is offering an... - March 16, 2022

MacroArray Diagnostics GmbH (MADx) Partners with ALPCO to Offer a Fully Automated Sample-to-Answer Multiplex Allergy Test Solution to the North American Market

ALPCO (Salem, NH), a leading US producer of novel immunoassay testing platforms, recently announced an exclusive distribution partnership with MacroArray Diagnostics GmbH (Vienna, Austria). Together, they offer a comprehensive line of testing solutions for allergies (IgE-based) and food intolerances (IgG-based), from test material to proprietary hardware and software to process and analyze samples. - February 01, 2022

Erica Cai Named ALPCO’s Summer 2020 Diabetes Research Travel Grant Recipient

Erica Cai Named ALPCO’s Summer 2020 Diabetes Research Travel Grant Recipient

Today ALPCO announced Erica Cai from Harvard Medical School as the latest recipient of its Diabetes Research Travel Grant. Dr. Cai is a postdoctoral fellow from the Joslin Diabetes Center researching the mechanism of autoimmunity that leads to beta cell destruction and type 1 diabetes (T1D). Dr. - November 10, 2020

Ampersand Capital Partners Acquires American Laboratory Products Company

American Laboratory Products Company, Ltd. (ALPCO), a specialty in vitro diagnostics company, today announced the majority recapitalization of the company by Ampersand Capital Partners. Ampersand’s investment will be used to support ALPCO’s worldwide growth initiatives, including the... - September 21, 2020

Marlena Holter Named ALPCO’s Winter 2020 Diabetes Research Travel Grant Recipient

Marlena Holter Named ALPCO’s Winter 2020 Diabetes Research Travel Grant Recipient

ALPCO's Winter 2020 Diabetes Research Travel Grant has been awarded to Marlena Holter, a DVM/PhD candidate from Cornell University’s College of Veterinary Medicine. Ms. Holter’s novel research focuses on GLP-1 regulated glucose regulation following vertical sleeve gastrectomy surgery to define the mechanisms underlying type 2 diabetes remission and metabolic improvement following bariatric surgery. - April 14, 2020

ALPCO Announces Deadline for Winter 2020 Diabetes Research Travel Grant Award

ALPCO Announces Deadline for Winter 2020 Diabetes Research Travel Grant Award

ALPCO announced the submission deadline for its Winter 2020 Diabetes Research Travel Grant Award. Each recipient is awarded up to $2500 to present their research at a relevant conference and a $2500 product credit. - December 04, 2019

ALPCO Launches Analytically Specific Human and Rodent STELLUX® Glucagon ELISA

ALPCO Launches Analytically Specific Human and Rodent STELLUX® Glucagon ELISA

ALPCO's new STELLUX® Chemiluminescence Glucagon ELISA features increased analytical specificity and a broad range to accurately quantify glucagon levels between 0.86 and 143.7 pmol/L (3-500 pg/mL) in human and rodent samples. - November 06, 2019

ALPCO’s New Fecal Calprotectin ELISA with Superior Clinical Accuracy Receives FDA 510(k) Clearance

ALPCO’s New Fecal Calprotectin ELISA with Superior Clinical Accuracy Receives FDA 510(k) Clearance

ALPCO received 510(k) clearance from the US FDA for its new fecal Calprotectin Chemiluminescence ELISA test. The ALPCO Calprotectin Chemiluminescence ELISA’s superior clinical accuracy will enable clinical laboratories to provide the most accurate results to gastroenterologists facing the challenges of differentiating IBD from IBS. - October 30, 2019

ALPCO Announces January 2019 Young Investigator Award Recipient of Its Diabetes Research Travel Grant

ALPCO Announces January 2019 Young Investigator Award Recipient of Its Diabetes Research Travel Grant

ALPCO awards its January 2019 Diabetes Research Travel Grant to Lisa Volpatti at Massachusetts Institute of Technology. - February 05, 2019

ALPCO Launches FDA Class I Exempt STELLUX® Glucagon ELISA

ALPCO Launches FDA Class I Exempt STELLUX® Glucagon ELISA

ALPCO announces launch of its new highly specific FDA Class I Exempt STELLUX® Chemi Glucagon ELISA. - October 23, 2018

ALPCO Announces Inaugural Young Investigators Award Recipient

ALPCO Announces Inaugural Young Investigators Award Recipient

ALPCO announces the first recipient of its new young investigators award, the Diabetes Research Travel Grant. - October 17, 2018

ALPCO’s Quality Management System Receives ISO 13485:2016 Certification

ALPCO’s Quality Management System Receives ISO 13485:2016 Certification

ALPCO announces that its quality management system recently received the distinguished ISO 13485:2016 certification from Intertek to ensure the quality, safety and efficacy of its products in the clinical diagnostics field. - October 09, 2018

ALPCO to Exhibit at the AACC’s 70th Annual Scientific Meeting and Clinical Lab Expo

ALPCO to Exhibit at the AACC’s 70th Annual Scientific Meeting and Clinical Lab Expo

ALPCO will promote the expansion of its STELLUX® Chemiluminescence ELISA platform, as well as its current therapeutic drug monitoring portfolio, gastroenterology testing panel, and assay qualification program at AACC’s 70th Annual Clinical Lab Expo. - July 25, 2018

ALPCO and InSphero Partner to Offer a Complete Solution to Assess Beta-cell Function in Islet Microtissue Culture Models

ALPCO and InSphero Partner to Offer a Complete Solution to Assess Beta-cell Function in Islet Microtissue Culture Models

ALPCO and InSphero announce partnership to provide customers with a complete solution to assess beta-cell function in islet microtissue culture models. - July 24, 2018

ALPCO Releases STELLUX® Chemi Active GLP-1 (7-36) Amide ELISA to Accurately Quantify Fasted Levels

ALPCO Releases STELLUX® Chemi Active GLP-1 (7-36) Amide ELISA to Accurately Quantify Fasted Levels

ALPCO, a leading producer of research and clinical immunoassays, recently announced the launch of its STELLUX® Chemi Active GLP-1 (7-36) amide ELISA. The chemiluminescence ELISA features increased sensitivity to accurately quantify active GLP-1 (7-36) amide levels as low as 1.5 pg/mL with a 25... - July 17, 2018

ALPCO to Feature New STELLUX® Chemi Active GLP-1 (7-36) amide ELISA and Young Investigators Travel Grant Program at ADA’s 78th Scientific Sessions

ALPCO to Feature New STELLUX® Chemi Active GLP-1 (7-36) amide ELISA and Young Investigators Travel Grant Program at ADA’s 78th Scientific Sessions

ALPCO will promote its new STELLUX® Chemi Active GLP-1 (7-36) amide ELISA and Young Investigators Travel Grant Program at the American Diabetes Association’s 78th Scientific Sessions June 22-26, 2018 in Orlando, FL. - June 19, 2018

ALPCO to Highlight Assay Qualification Program at the AACC’s 69th Annual Scientific Meeting and Clinical Lab Expo

ALPCO to Highlight Assay Qualification Program at the AACC’s 69th Annual Scientific Meeting and Clinical Lab Expo

ALPCO announced it will feature a variety of products supported by its assay qualification program at the AACC’s 69th Annual Scientific Meeting and Clinical Lab Expo in San Diego August 1-3, 2017. Among these products is the Easy Stool Extraction Device and a Therapeutic Drug Monitoring ELISA portfolio. - July 25, 2017

ALPCO Offering Demonstrations of STELLUX® Chemiluminescent Plate Reader at ADA's 77th Scientific Sessions

ALPCO Offering Demonstrations of STELLUX® Chemiluminescent Plate Reader at ADA's 77th Scientific Sessions

The STELLUX® Chemiluminescent Plate Reader offers a simple plug-and-play setup, and is the ideal size for any lab. ALPCO’s Field Applications Scientist will be on-site at the ADA’s 77th Scientific Sessions offering live demonstrations of the new STELLUX® Chemiluminescent Plate Reader. - June 07, 2017

ALPCO and InSphero Collaborate at the ADA's 77th Scientific Sessions to Advance Metabolic Disease Research

ALPCO and InSphero Collaborate at the ADA's 77th Scientific Sessions to Advance Metabolic Disease Research

ALPCO and InSphero will team up at the ADA’s 77th Scientific Sessions to enhance the study of islet function, regeneration, and preservation by providing researchers with methods to perform 3D islet microtissue culture, as well as assays for measuring glucagon secretion and glucose-regulated insulin assays. - June 06, 2017

ALPCO to Launch New Zonulin ELISAs and Therapeutic Drug Monitoring Assays for IBD at Digestive Disease Week®

ALPCO to Launch New Zonulin ELISAs and Therapeutic Drug Monitoring Assays for IBD at Digestive Disease Week®

ALPCO will launch new gastrointestinal and inflammatory bowel disease (IBD) assays at Digestive Disease Week® May 7-9, 2017 in Chicago, IL. Included in this launch are two Zonulin ELISAs for the study of gut permeability and celiac disease, as well as therapeutic drug monitoring assays for IBD. - May 02, 2017

New Gastrointestinal Pathogen Assays Available from ALPCO

New Gastrointestinal Pathogen Assays Available from ALPCO

ALPCO is now offering a line of research assays for the investigation of common bacterial and parasitic gastrointestinal (GI) pathogens including Giardia lamblia, Cryptosporidium spp., Blastocystis hominis, Entamoeba histolytica/dispar, and Clostridium difficile. These assays can be used to... - November 15, 2016

New Ultrasensitive Active GLP-1 ELISA to Confidently Measure Fasted Levels of Active GLP-1

New Ultrasensitive Active GLP-1 ELISA to Confidently Measure Fasted Levels of Active GLP-1

ALPCO has released its new STELLUX® Chemiluminescent Ultrasensitive Active GLP-1 ELISA, the most sensitive active GLP-1 assay on the market. - November 09, 2016

ALPCO Releases Versatile and Economical Chemiluminescent Plate Reader

ALPCO Releases Versatile and Economical Chemiluminescent Plate Reader

ALPCO has launched its new STELLUX® Chemiluminescent Plate Reader, an economical and versatile system for any size lab. - September 20, 2016

ALPCO’s New and Improved Adiponectin ELISAs Allow Researchers to Confidently Study Type 2 Diabetes

ALPCO’s New and Improved Adiponectin ELISAs Allow Researchers to Confidently Study Type 2 Diabetes

ALPCO has released new and improved versions of their Total Adiponectin and HMW & Total Adiponectin ELISAs which allow researchers to confidently measure adiponectin for the study of high molecular weight (HMW) to total ratios. - August 17, 2016

ALPCO Releases New Broad Range Periostin ELISA

ALPCO Releases New Broad Range Periostin ELISA

ALPCO now has a new broad range Periostin ELISA capable of measuring elevated levels of periostin consistent with current research. - June 07, 2016

ALPCO’s Bioactive Leptin ELISA Allows Researchers to Differentiate Between Leptin Resistance and Non-functional Leptin

ALPCO’s Bioactive Leptin ELISA Allows Researchers to Differentiate Between Leptin Resistance and Non-functional Leptin

ALPCO recently announced the release of its Bioactive Leptin ELISA, offering diabetes and obesity researchers a new tool to differentiate between leptin resistance and non-functional leptin. The assay allows for the measurement of leptin in human serum through the process of binding leptin to... - April 26, 2016

ALPCO's New Chemiluminescent IL-6 ELISA Delivers Flexibility and Cost Savings

ALPCO's New Chemiluminescent IL-6 ELISA Delivers Flexibility and Cost Savings

ALPCO announced the launch of its new STELLUX® Chemi Human IL-6 ELISA - the first cytokine assay in the STELLUX® Chemiluminescence product line. - April 06, 2016

ALPCO's New NT-proBNP ELISA Offers Cost Savings and Flexibility

ALPCO's New NT-proBNP ELISA Offers Cost Savings and Flexibility

ALPCO recently announced the release of its new NT-proBNP (1-76) ELISA, offering researchers investigating cardiovascular disease, kidney disease, and diabetes with a flexible, user friendly and cost effective tool. The assay is highly characterized to measure changes in levels of NT-proBNP, and... - February 23, 2016

ALPCO Releases New Basophil Activation Test Validated for the Evaluation of Kinase Inhibitors in Early Drug Development

ALPCO Releases New Basophil Activation Test Validated for the Evaluation of Kinase Inhibitors in Early Drug Development

ALPCO has released its new InhibiScreen Basophil Activation Test (BAT) which was developed and validated specifically for the evaluation of kinase inhibitors during early drug development. - February 16, 2016

ALPCO's New Stool-Based Gastroenterology Assays and Extraction Method Can Improve Lab Sample Processing Time by Up to 86%

ALPCO's New Stool-Based Gastroenterology Assays and Extraction Method Can Improve Lab Sample Processing Time by Up to 86%

ALPCO recently launched a new panel of 13 stool-based gastroenterology assays that are all compatible with one single extraction step, allowing labs to improve sample processing time by up to 86%. - January 26, 2016

ALPCO Releases New STELLUX® Chemiluminescent Adiponectin ELISAs

ALPCO Releases New STELLUX® Chemiluminescent Adiponectin ELISAs

ALPCO has launched its new STELLUX® Chemiluminescent Total Adiponectin and HMW Adiponectin ELISAs. - August 25, 2015

ALPCO and Cisbio US, Inc. Announce Sales and Distribution Agreement

ALPCO and Cisbio US, Inc. Announce Sales and Distribution Agreement

Starting on July 1, Cisbio US, Inc. will have exclusive access to ALPCO's colorimetric and STELLUX® Chemiluminescent Diabetes and Obesity products. - July 01, 2015

ALPCO Launches New and Improved Website for Customers

ALPCO Launches New and Improved Website for Customers

ALPCO recently launched a brand new website. The site was designed and developed to offer their customers a new and improved experience when searching for and buying immunoassay products. The website’s key features allow for more intuitive browsing and navigation on any device. ALPCO’s... - June 16, 2015

ALPCO Releases New Chemiluminescent Human C-peptide ELISA

ALPCO Releases New Chemiluminescent Human C-peptide ELISA

ALPCO adds to their STELLUX® Chemiluminescent line of assays with the launch of the new Human C-peptide ELISA. - December 10, 2014

New Pancreatic Cell Antibodies from ALPCO Allow Researchers to Identify and Isolate Major Pancreatic Cell Types

New Pancreatic Cell Antibodies from ALPCO Allow Researchers to Identify and Isolate Major Pancreatic Cell Types

A new menu of pancreatic cell antibodies for the identification and isolation of major human pancreatic cell types is now available from ALPCO. - August 07, 2014

ALPCO Launches Antibodies Supporting Pancreatic Cancer Research

ALPCO Launches Antibodies Supporting Pancreatic Cancer Research

In response to recent reports that pancreatic cancer deaths are on the rise globally, ALPCO has released a line of pancreatic antibodies to provide the research community with reliable tools that can be used to better analyze and understand pancreatic cancer. - July 29, 2014

ALPCO Expands EuroFlow™ Product Offering with the Addition of Plasma Cell Dyscrasias Screening Tube

ALPCO Expands EuroFlow™ Product Offering with the Addition of Plasma Cell Dyscrasias Screening Tube

ALPCO has expanded EuroFlow™ product offering with addition of the Plasma Cell Screening Tube from Cytognos S.L. - April 03, 2014

ALPCO Releases STELLUX™ Chemiluminescent Human Intact Proinsulin ELISA

ALPCO Releases STELLUX™ Chemiluminescent Human Intact Proinsulin ELISA

ALPCO has launched their new STELLUX™ Chemi Human Intact Proinsulin ELISA, the latest addition to their chemiluminescent product line. - February 18, 2014

ALPCO's New FDA Cleared 25-OH Vitamin D Total ELISA Provides Option for Hospitals and Smaller Clinical Labs to Bring Affordable Testing In-House

ALPCO's New FDA Cleared 25-OH Vitamin D Total ELISA Provides Option for Hospitals and Smaller Clinical Labs to Bring Affordable Testing In-House

ALPCO expands test portfolio for clinical and hospital laboratory customers with the release of a FDA 510(k) cleared 25-OH Vitamin D Total ELISA. - January 22, 2014

ALPCO Releases STELLUX™ Chemiluminescence Human Total Proinsulin ELISA

ALPCO Releases STELLUX™ Chemiluminescence Human Total Proinsulin ELISA

A new Human Total Proinsulin ELISA is launched in ALPCO's STELLUX™ Chemiluminescent line of assays. - November 19, 2013

ALPCO Expands Product Offering with Addition of Mouse-Specific Flow Cytometry Reagents

Earlier this year, ALPCO began offering flow cytometry reagents and data analysis software. As promised, the company has recently added high quality and affordable mouse reagents to their growing flow cytometry portfolio. Among the 600 new mouse reagents are antibodies for CD3, CD4, CD8 and... - October 29, 2013

ALPCO Launches STELLUX™ Chemiluminescent Human Insulin ELISA

ALPCO Launches STELLUX™ Chemiluminescent Human Insulin ELISA

ALPCO releases second chemiluminescent assay in STELLUX™ product line. - October 24, 2013

ALPCO to Distribute NAG Assays from PPR Diagnostics

ALPCO to Distribute NAG Assays from PPR Diagnostics

New distribution agreement allows ALPCO to distribute NAG assays from PPR Diagnostics. - June 13, 2013

Mouse Osteopontin ELISA Now Available from ALPCO

Mouse Osteopontin ELISA Now Available from ALPCO

ALPCO launches the second species-specific kit in a line of Osteopontin ELISAs. - May 31, 2013

ALPCO to Exhibit with BÜHLMANN Laboratories at DDW 2013 and Feature Fecal Calprotectin ELISA

ALPCO to Exhibit with BÜHLMANN Laboratories at DDW 2013 and Feature Fecal Calprotectin ELISA

The partnering companies will feature BÜHLMANN's Fecal Calprotectin ELISA that is pending FDA clearance for IVD use in the United States. - May 16, 2013

ALPCO Adds FDA Registered Renin RIA from Cisbio to Product Offering

ALPCO Adds FDA Registered Renin RIA from Cisbio to Product Offering

ALPCO now offering a line of RIA products from Cisbio in the United States. - May 07, 2013

ALPCO Launches Human Osteopontin ELISA

ALPCO Launches Human Osteopontin ELISA

ALPCO launches the first assay in a new line of species-specific Osteopontin ELISAs. - May 01, 2013

ALPCO Expands Product Offering with EuroFlow™ Flow Cytometry Reagents and Infinicyt™ Analytical Software from Cytognos S.L.

ALPCO Expands Product Offering with EuroFlow™ Flow Cytometry Reagents and Infinicyt™ Analytical Software from Cytognos S.L.

Starting April 30, 2013 ALPCO will begin offering flow cytometry solutions from Cytognos S.L. - April 30, 2013

ALPCO Launches Their First STELLUX Chemiluminescent ELISA

ALPCO Launches Their First STELLUX Chemiluminescent ELISA

ALPCO announces the launch of their STELLUX Rodent Insulin ELISA, the first ELISA launched in their new STELLUX Chemiluminescent assay product line. - April 26, 2013

Press Releases 1 - 50 of 80